FIORETTO, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.027
AS - Asia 6.428
EU - Europa 3.939
AF - Africa 1.539
SA - Sud America 1.227
OC - Oceania 143
Continente sconosciuto - Info sul continente non disponibili 82
Totale 28.385
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.254
SG - Singapore 2.358
HK - Hong Kong 1.024
CN - Cina 968
BR - Brasile 707
IT - Italia 649
FI - Finlandia 503
VN - Vietnam 360
DE - Germania 345
SE - Svezia 212
UA - Ucraina 204
PL - Polonia 196
FR - Francia 193
RU - Federazione Russa 181
IN - India 149
GB - Regno Unito 127
NL - Olanda 111
JP - Giappone 98
AR - Argentina 89
MX - Messico 79
IQ - Iraq 76
EC - Ecuador 75
PH - Filippine 66
AT - Austria 65
TR - Turchia 65
ES - Italia 64
ZA - Sudafrica 61
IE - Irlanda 60
TH - Thailandia 59
CO - Colombia 56
ID - Indonesia 56
NP - Nepal 56
UZ - Uzbekistan 56
NO - Norvegia 55
PE - Perù 55
JO - Giordania 54
BJ - Benin 53
AO - Angola 52
MK - Macedonia 52
AZ - Azerbaigian 51
PY - Paraguay 51
SK - Slovacchia (Repubblica Slovacca) 51
RO - Romania 50
CI - Costa d'Avorio 49
PS - Palestinian Territory 49
AL - Albania 48
KR - Corea 48
LU - Lussemburgo 48
UY - Uruguay 48
TN - Tunisia 47
TW - Taiwan 47
CW - ???statistics.table.value.countryCode.CW??? 46
BG - Bulgaria 45
CA - Canada 45
CL - Cile 45
DK - Danimarca 45
GA - Gabon 45
AM - Armenia 44
BY - Bielorussia 44
HN - Honduras 44
PA - Panama 44
BB - Barbados 43
KE - Kenya 43
SN - Senegal 43
TJ - Tagikistan 43
AD - Andorra 42
GM - Gambi 42
LV - Lettonia 42
MY - Malesia 42
RW - Ruanda 42
YT - Mayotte 42
AE - Emirati Arabi Uniti 41
CM - Camerun 41
GH - Ghana 41
GT - Guatemala 41
LB - Libano 41
MA - Marocco 41
SA - Arabia Saudita 41
SI - Slovenia 41
CY - Cipro 40
CZ - Repubblica Ceca 40
KZ - Kazakistan 40
MD - Moldavia 40
BF - Burkina Faso 39
CG - Congo 39
HU - Ungheria 39
IR - Iran 39
ME - Montenegro 39
MG - Madagascar 39
MN - Mongolia 39
MR - Mauritania 39
PK - Pakistan 39
SO - Somalia 39
CD - Congo 38
CV - Capo Verde 38
GE - Georgia 38
IS - Islanda 38
KG - Kirghizistan 38
KH - Cambogia 38
RE - Reunion 38
Totale 26.545
Salva come PNG Salva come JPEG
Città #
Fairfield 2.102
Ashburn 1.339
Woodbridge 1.293
Singapore 1.225
Houston 1.107
Hong Kong 949
Ann Arbor 862
Cambridge 719
Seattle 704
Chandler 702
Wilmington 698
Jacksonville 654
Princeton 336
Boardman 309
San Jose 284
Helsinki 264
Los Angeles 242
Beijing 227
Santa Clara 195
San Diego 185
Medford 154
Bytom 144
Chicago 130
Padova 126
Nanjing 123
Ho Chi Minh City 118
Des Moines 110
Roxbury 107
Munich 93
New York 79
Guangzhou 75
Hanoi 71
São Paulo 62
Amman 52
Council Bluffs 49
Rome 48
Baku 47
Dublin 47
Cotonou 46
Milan 46
Pune 46
Salt Lake City 46
Tashkent 46
Dong Ket 44
Libreville 44
Abidjan 43
Luanda 43
Dakar 42
Bridgetown 41
Kigali 40
Riga 40
Accra 39
Shenyang 39
Andorra la Vella 38
Buffalo 38
Dushanbe 38
Montevideo 38
Ulan Bator 38
Vienna 38
Nouakchott 37
Phnom Penh 37
Conakry 36
Hebei 36
Minsk 36
Nairobi 36
Panama City 36
Bamako 35
Nuremberg 35
Willemstad 35
Harare 34
Noumea 34
Yerevan 34
Kampala 33
Kinshasa 33
Managua 33
Turku 33
Antananarivo 32
Kingstown 32
Lima 32
Nassau 32
Tianjin 32
Bishkek 31
Castries 31
Luxembourg 31
Cayenne 30
Podgorica 30
Praia 30
Tokyo 30
Warsaw 30
Djibouti 29
Jiaxing 29
Lusaka 29
Mamoudzou 29
Nanchang 28
Norwalk 28
Ouagadougou 28
San José 28
Tallinn 28
Brazzaville 27
Hefei 27
Totale 18.210
Salva come PNG Salva come JPEG
Nome #
Modifications of Resting Energy Expenditure After Sleeve Gastrectomy 305
Characterization of subcutaneous and omental adipose tissue in patients with obesity and with different degrees of glucose impairment 280
Treatment with dapagliflozin increases FGF-21 gene expression and reduces triglycerides content in myocardial tissue of genetically obese mice 277
Expanding the therapy options for diabetic kidney disease 269
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table 265
Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19 239
Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration 239
The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience 232
High-protein diet: a barrier for sodium-glucose co-transporters 2 inhibitors nephroprotective effects? 231
Incidence and Predictors of Hypoglycemia 1 Year After Laparoscopic Sleeve Gastrectomy 230
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study 229
Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study 218
Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. 209
A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus 207
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin 204
SGLT2 Inhibitors and the Diabetic Kidney 200
Acute phase markers of inflammation and glomerular structure in type 2 diabetic patients 198
Diagnostic pathways of the complex patients: rapid intensive observation in an Acute Medical Unit. 192
Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients 190
Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study 189
Mechanisms linking empagliflozin to cardiovascular and renal protection 188
Role of insulin and atrial natriuretic peptide in sodium retention in insulin-treated IDDM patients during isotonic volume expansion. 185
Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable 183
Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. 179
The effects of SGLT2 inhibitors on metabolic phenotype and FGF-21 expression from the adipose tissue and the liver are less pronounced in ob/ob mice 179
Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative 178
Obesity and COVID-19: an Italian snapshot 175
Overall quality of care predicts the variability of key risk factors for complications in type 2 diabetes: An observational, longitudinal retrospective study 173
SARS-CoV-2 identification and IgA antibodies in saliva: One sample two tests approach for diagnosis 172
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus 168
Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes 166
Impaired Response To Angiotensin-ii In Type-1 (insulin-dependent) Diabetes-mellitus - Role of Prostaglandins and Sodium-lithium Countertransport Activity 165
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study 165
SARS-CoV-2 RNA identification in nasopharyngeal swabs: Issues in pre-analytics 165
Sudden death with massive hemoptysis from aortobronchial fistula 163
Bariatric surgery improves atherogenic LDL profile by triglyceride reduction 159
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study. 157
Antihypertensive treatment and multifactorial approach for renal protection in diabetes 155
Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. 155
Five-year predictors of insulin initiation in people with type 2 diabetes under real-life conditions 155
Apparent treatment resistant hypertension, blood pressure control and the progression of chronic kidney disease in patients with type 2 diabetes 152
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects 149
Ketone bodies increase glomerular filtration rate in normal man and in patients with Type 1 (insulin-dependent) diabetes mellitus 149
Type I insulin-dependent diabetic patients show an impaired renal hemodynamic response to protein intake. 148
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia 148
Atherogenic dyslipidemia and diabetic nephropathy 148
Cardiac injury and mortality in patients with Coronavirus disease 2019 (COVID-19): insights from a mediation analysis 148
Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. 147
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment 147
Residual macrovascular risk in 2013: what have we learned? 146
Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals 145
Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. 144
Metabolic control of kidney hemodynamics in normal and insulin-dependent diabetic subjects. Effects of acetoacetic, lactic, and acetic acids. 144
Patterns of renal injury in NIDDM patients with microalbuminuria 143
RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia 140
Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance 140
Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes 140
Is podocyte injury relevant in diabetic nephropathy? Studies in type 2 diabetic patients. 140
A defect in glycogen synthesis characterizes insulin resistance in hypertensive patients with type 2 diabetes 139
The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint. 139
Biological Variability of Estimated GFR and Albuminuria in CKD 139
Reversibility of diabetic nephropathy lesions: a new concept 137
Role of Atrial-natriuretic-peptide In the Pathogenesis of Sodium Retention In Iddm With and Without Glomerular Hyperfiltration 137
Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. 136
In hospital risk factors for acute kidney injury and its burden in patients with Sars-Cov-2 infection: a longitudinal multinational study 136
Normoalbuminuric kidney impairment in patients with T1DM: Insights from annals initiative 135
Is diabetic nephropathy inherited? Studies of glomerular structure in type 1 diabetic sibling pairs. 134
Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure 134
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies 134
The kidney in diabetes: dynamic pathways of injury and repair. 132
Impaired renal response to a meat meal in insulin-dependent diabetes: role of glucagon and prostaglandins. 132
Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients 131
Renal protection in diabetes: role of glycemic control. 130
Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. 130
Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria 130
Renal structure and function in non-insulin dependent diabetic patients with microalbuminura 129
Glucose and ketone body turnover in carnitine-palmitoyl-transferase deficiency. 128
Potassium management with finerenone: Practical aspects 127
Association of the Q121 Variant of ENPP1 Gene With Decreased Kidney Function Among Patients With Type 2 Diabetes. 126
Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes 126
Growth factors and diabetic nephropathy: kidney structure and therapeutic interventions. 125
Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference 125
Predictors of chronic kidney disease in type 1 diabetes: A longitudinal study from the AMD Annals initiative 125
Porcine and human insulin absorption from subcutaneous tissues in normal and insulin dependent diabetic subjects: a deconvolution-based approach 124
Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. 124
Vascular endothelial growth factor expression in microdissected glomeruli of type 2 diabetic patients. 123
Current Smoking is Not Associated with COVID-19 123
Time-series analysis of multidimensional clinical-laboratory data by dynamic Bayesian networks reveals trajectories of COVID-19 outcomes 123
Histopathology of diabetic nephropathy. 122
Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes 122
Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes 122
The effect of dapagliflozin on renal function in patients with type 2 diabetes 122
Relationships Among Natriuresis, Atrial-natriuretic-peptide and Insulin In Insulin-dependent Diabetes 122
PC-1 aminoacid variant Q121 is associates with lower glomerular filtration rate in type 2 diabetic patients with abnormal albumin excretion rate. 121
Mesangial expansion in diabetic nephropathy: functional and genetic considerations. 120
Diabetic Nephropathy 120
Renal structure in type 2 diabetes 120
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. 120
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation 119
The kidney in type 2 diabetes: focus on renal structure. 119
Totale 15.968
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.057
article - articoli 77.548
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.906
Totale 164.511
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.337 0 0 0 0 0 0 75 201 343 176 285 257
2021/20222.431 98 283 253 193 145 120 104 263 126 68 245 533
2022/20231.622 453 136 20 142 304 204 2 111 170 12 52 16
2023/2024971 32 118 78 72 69 138 74 45 18 56 138 133
2024/20254.133 27 362 182 171 520 104 265 289 398 204 622 989
2025/202610.633 586 1.442 2.429 2.706 1.637 897 936 0 0 0 0 0
Totale 28.577